Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP) - Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)

Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 80 人开始时间: 2011年3月30日最近更新: 2023年10月17日

试验速览

See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html

•1) synchronous or metachronous active malignancies 2) allergy to a contrast agent 3) any of the followings: i) inappropriate secretion of antidiuretic hormone (SIADH) ii) ectopic ACTH syndrome iii) Lambert-Eaton myasthenic syndrome iv) subacute cerebellar degeneration v) paraneoplastic encephalomyelitis / sensory neuropathy 4) infection requiring systemic treatment 5) fever of 38 degrees centigrade or higher within 24 hours before registration 6) pregnant or lactating women 7) psychotic disorder 8) receiving systemic steroid therapy 9) unstable angina or myocardial infarction within the past 6 months 10) uncontrolled hypertension 11) uncontrolled diabetes mellitus or administration of insulin 12) interstitial pneumonitis or lung fibrosis identified by a chest X-ray, or severe pulmonary emphysema

发起方

Japan Clinical Oncology Group (JCOG)